Kornimate/medical-research-clean huggingface dataset:
impact on the nutritional state and the quality of life

Conditions: Cancer

Summary: the prevalence of malnutrition in cancerous patients varies between 50% and 80%. it is variable in function: the location and the extension of the tumor, of the general state , of age, of the socio-economic class and the pain. the health consequences of a malnutrition are very important: aggravation of the state of health, complications of treatment, hospitalization, alteration of the quality of life and decrease the survival, and the treatment response. nutrition being very important in patients, there are recommendations for the nutritional care of these patients, formulated by the european society for clinical nutrition and metabolism. the investigators do not know to what extent these recommendations are respected in practice and their influence on the nutritional status and the quality of life of patients. the investigators therefore propose to assess the conformity of the nutritional care patients in clinical practice in relation to the european recommendations and in a second time to assess the influence of this compliance or non-compliance on the nutritional status clinical and biological of cancerous patients under chemotherapy, on their quality of life, on their response to treatment and on their survival. the investigators will try to identify factors that may be linked to the non-compliance such as the characteristics of the cancer disease, socio-demographic characteristics of the subject and the factors related to the structure in which it is supported.


Eligibility criteria:
inclusion criteria: * 18-year-old subject in 85 years in the inclusion * subject presenting a cancerous pathology requiring a systematic treatment by exclusive chemotherapy for a minimal duration of three months with a plan of 3 cures of chemotherapy with an interval between the cures of 21 days * presenting subject one of these 4 cancerous pathologies: cancer of the aéro-digestive ways superiors, sarcomas, colorectal cancers, broncho-lung cancers * subject having the capacity of lira and to understand(include) french * subject having signed lit(enlightened) consent * subject taken care for its cancerous pathology in one of the partner services of the project * subject affiliated to the national insurance scheme exclusion criteria: * subject having benefited from a major surgical operation in 4 weeks preceding the inclusion * subject having benefited from a radiotherapy in two weeks before the inclusion * subject minor(miner), pregnant woman, subject incapable to give its consent, subject under supervision(guardianship) - guardianship

Keywords: chemotherapy
enteral feeding in the post-injury open abdomen

Conditions: Trauma to the Abdomen

Summary: the purpose of this study is to determine if enteral feeding (en) in patients with a traumatic bowel injury requiring an open abdomen impacts outcomes. patients who receive en will be compared to those who remain nil-per-os (npo). additionally, an internal study control will be performed by analyzing concurrent injured patients requiring an open abdomen who did not have a bowel injury. specific aims: hypothesis 1: en in patients with a traumatic bowel injury requiring an open abdomen improves fascial closure rate compared to patients who remain npo. hypothesis 2: en in patients with a traumatic bowel injury requiring an open abdomen reduces infectious complications compared to patients who remain npo. hypothesis 3: en in patients with a traumatic bowel injury requiring an open abdomen have a lower mortality rate compared to patients who remain npo.

fascial closure is determine by the primary physician and should be recorded in the operative record. this record will be accessed to determine if this variable is accomplished. additionally, any dehiscence complication will be recorded (which would impact the long-term fascial closure rate). infectious complications (abscess, pneumonia, etc) will be adjudicated by the primary clinician and any record of this in the patient chart will be recorded.

Eligibility criteria:
inclusion criteria: * all patients with a post-injury open abdomen exclusion criteria: * patients to be excluded from analysis include deaths within 24 hours, identification of injury \> 24 hours, and those transferred from an outside hospital \> 24 hours following initial injury.
virtual reality in the management of painful or anxiety-provoking procedures in emergency departments

Conditions: Pain and Anxiety; Dislocation; Suture

Summary: study and evaluate the effectiveness of virtual reality in pain management.

study and evaluate the effectiveness of virtual reality in pain management.this is an open prospective observational study carried out at urgences fattouma bourgiba monastir. for all patients included, a data collection form must be completed, mentioning age, sex, medical and surgical history, and the type of procedure planned. * if initial vas \>5 and intolerable: patients will immediately use painkillers and will be excluded from the study. * if initial vas \ 5 but tolerable: only vr glasses are used as an analgesic. if during the procedure the patient describes intolerable pain: the vas will be noted, and the patient will use a rescue analgesic (intranasal ketamine or other at the discretion of the attending physician). the vr device consists of a pair of vr glasses with a video previously chosen and installed. patient preparation must be done before initiating the protocol. the first step is to choose patient candidates for vr who are understanding and interested. guardian approval is required; then it is necessary to explain the principle, the stages and the benefits of the care. the intensity of pain is calculated according to the visual analog scale before, during the procedure and 30 minutes after as well as the max vas during the procedure, the 'children fear scale', the satisfaction score and any adverse effects are noted.

Eligibility criteria:
inclusion criteria: * patients aged 09 and 24 years * suturing a wound * changing a dressing * lumbar puncture, * peripheral venous line * blood test * intramuscular injection * reduction of a fracture * casting or plastering. exclusion criteria: * impaired consciousness * epilepsy * wound/infection covering the helmet area * headache * intellectual/mental retardation * nausea, vomiting * patient already included in the protocol * pain requiring immediate medical attention. analgesic (vas \>5 and described as intolerable).
personalised timing of interval debulking surgery based on kelim after neoadjuvant chemotherapy in advanced ovarian cancer - a pilot study

Conditions: Ovarian Cancer

Summary: about 70% of epithelial ovarian cancer patients are diagnosed at advanced stage. when primary optimal surgery is not possible, neoadjuvant chemotherapy will followed by interval debulking surgery is one treatment option. however, there is no consensus on the optimal timing of the surgery. ca125 is a well-known tumor marker in ovarian cancer. its kinetic change has been proven to correlate with the patients' response to chemotherapy and chance of optimal resection. this study aims to utilize the kinetic change of ca125 to customize the timing of surgery for individual patients.

recruited patients will have additional ca125 at 4th (before administration of chemotherapy), and 5th week after the first cycle of chemotherapy. kelim will be determined. patients with kelim =\>1 will receive radiological assessment and undergo internal debulking surgery if the disease is operable. patients with kelim \<1 will have alternative management, such as addition of bevacizumab or changing to dose-dense chemotherapy, and defer the interval debulking surgery

Eligibility criteria:
inclusion criteria: 1. patients must be at least 18 years old. 2. patients who have eastern cooperative oncology group (ecog) score 0-1. 3. patients who are competent to give informed consent. 4. patients who have stage iii-iv histologically or cytologically confirmed eoc, fallopian tube or primary peritoneal cancer not amenable for pds. 5. patients who are planned for nact using platinum-based chemotherapy +/- bevacizumab or biosimilar. those who are receiving nact before ids are also eligible. 6. patients who have an evaluable ca125 level at baseline (i.e., baseline level is at least 2x upper limit of normal). 7. patients who have baseline computed tomography of at least abdomen and pelvis, or positron emission tomography (pet)-ct. magnetic resonance imaging (mri) is also acceptable but the same modality has to be used when assessing the feasibility of ids. 8. patients who agree to undergo ids, where the time of ids may differ from the usual clinical practice. 9. patients who agree to receive adjuvant chemotherapy, if clinically indicated. the total number of chemotherapy should be at least four or above. exclusion criteria: 1. patients who have borderline malignancy, or non-epithelial ovarian cancer like germ cell or sex cord tumor, or metastatic diseases from other origins like krukenberg's tumor 2. patients who are eligible for pds 3. patients who are not fit for pds because of medical morbidities or refusal of operation 4. patients who have already started nact outside the study centres, except those who have just had one cycle within 21 days and the baseline ca125 is available. 5. patients who are pregnant

Keywords: advanced ovarian cancer neoadjuvant chemotherapy interval debulking surgery kelim
the efficacy study of sodium hyaluronate to treat symptomatic hip osteoarthritis

Conditions: Symptomatic Hip Osteoarthritis

Summary: to demonstrate the difference in terms of symptomatic efficacy between adant® sodium hyaluronate and placebo following an intra-articular injection in patients with symptomatic osteoarthritis of the hip. each patient will receive an injection of sodium hyaluronate or placebo in the symptomatic hip and will be followed up for three months. at the third month, if the score for overall pain is still \> 40 mm on the vas, a second injection of adant® can be given irrespective of which treatment was received previously. the patient will be followed up for a further 3 months in an open-label fashion (monthly visits).


Eligibility criteria:
inclusion criteria: * 1. primary osteoarthritis of the hip defined according to the acr criteria; symptomatic, 2. osteoarthritis of radiological grade ii to iii according to the kellgren-lawrence classification, using x-rays performed during the last three months, 3. overall pain intensity between 40 and 80 mm on a vas of 100 mm at the pre-screening examination, 4. the patients experienced pain at least one in two days during the last 30 days, it was resistant to paracetamol treatment at a dose of 4 g/day and a step 2 analgesic or a nsaid taken for at least 10 days, 5. a prosthesis is not planned in the next six months. exclusion criteria: * women who are pregnant or breastfeeding or women who could become pregnant and are not using effective contraception, * major dysplasia (defined using lequesne's criteria as dislocation of the hip), * treatment by intra-articular injection of hyaluronic acid in the symptomatic hip during the 6 months prior to pre-screening, * patients with a history of hypersensitivity to any of the ingredients in the hyaluronan, * the presence of inflammatory arthropathy or another disorder or condition that could affect the joint (e.g., rheumatoid arthritis, metabolic bone disease, femoral head necrosis, psoriasis, gout, infection), * another muscular or skeletal condition that could interfere with the evaluation of the efficacy of the treatment on the hip in question (evaluation of pain or functional handicap), * systemic corticosteroid therapy or intra-articular injection of corticosteroids into the ipsilateral hip or knee within the last month, * intermittent claudication or vascular disease, * previous surgery on the hip in question, * septic arthritis at any site, * any surgical procedure, including arthroplasty or arthroscopy, to the hip during the six months prior to pre-screening or surgery scheduled during the trial, * any chronic skin condition that could affect the site of the injection, * use of the investigational treatment or material during the last three months, * oral or injectable anticoagulant treatment, * antiaggregant platelet treatment, particularly low-dose aspirin, * symptomatic chondrocalcinosis in the painful hip

Keywords: hip osteoarthritis hyaluronic acid viscosupplementation intra-articular injections
negative pressure wound therapy in the management of diabetic foot ulcers

Conditions: Diabetic Foot Ulcer

Summary: role of negative pressure wound therapy in the management of diabetic foot ulcers • the aim of this study will be to assess negative pressure wound therapy in treating diabetic foot ulcers.

diabetic foot ulcers are a major cause of admission in diabetic patients, and comprise a disproportionately high number of hospital days because of multiple surgical procedures and prolonged length of stay in hospital. the improvement in diabetes therapy and the reinforcement of guidelines have reduced the amputation rate. the approach to diabetic foot ulcers has allowed the availability of several medical options to ensure the best local condition and wound healing. negative-pressure wound therapy is a non-invasive therapy system that employs a controlled negative pressure using a vacuum device to promote wound healing by removing fluid from open wounds through a sealed dressing or a foam dressing connected to a container. an earlier study has shown that npwt reduced the need for subsequent amputations in a 6-month follow-up period. this reflects the importance of this device in management of dfus and prevents its complications. as most of the diabetic wounds present with infection, the success of npwt is still highly dependent upon the adequacy of surgical debridement and antimicrobial coverage. npwt provides a moist wound environment ideal for re-epithelialization, growth factor action, angiogenesis, and granulation promotion. edema reduction produced by npwt decreases interstitial pressure and positively promoting wound vessel formation and improving wound circulation and lymphatic drainage, increasing the availability of nutrients, oxygen and antibiotic therapy in the wound area. some studies showed that npwt promotes an improvement of balance between proteases and their inhibitors and influences cytokine modulation and promotes a positive wound environment. accurate classification of diabetic foot ulcers according to wagner's classification of ulcers is essential for inter-clinician communication, assessment of healing tendency during management by npwt.

Eligibility criteria:
inclusion criteria: * acute and chronic diabetic wounds, pressure ulcers. * wagener's grade i superficial diabetic ulcer. * wagener's grade ii after surgical debridement and an appropriate antibiotic therapy. * ischemic wounds after revascularization. exclusion criteria: * - wagener's grade iii, osteomyelitis and charcot's joint septic arthritis. * wagener's grade iv, localized gangrene e.g. toe ,heel. * wagener's grade v, extensive gangrene involving the whole foot. * septicemia. . * gas forming organism. * wounds resulting from venous insufficiency. * peripheral vascular disease (absent distal pulse). * patients being treated with corticosteroids, immunosuppressive drugs or chemotherapy * any other serious pre-existing cardiovascular, pulmonary and immunological disease.
axillary sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial cn1 breast cancer

Conditions: Sentinel Lymph Node Biopsy

Summary: slnb has been recommended by domestic and foreign guidelines for patients with initial cn1 and nac descending to ycn0. however, the best technical path is still not very clear at present, and the long-term tumor safety data is still insufficient. therefore, it is necessary to further explore the optimal technical pathway and long-term tumor safety for slnb in patients with initial cn1 and nac downgrading to ycn0 in the real world.this study will evaluate the optimized technical pathway and long-term tumor safety of slnb in patients with initial cn1 and nac downgrading to ycn0 in real-world studies.

slnb has been recommended by domestic and foreign guidelines for patients with initial cn1 and nac descending to ycn0. however, the best technical path is still not very clear at present, and the long-term tumor safety data is still insufficient. therefore, it is necessary to further explore the optimal technical pathway and long-term tumor safety for slnb in patients with initial cn1 and nac downgrading to ycn0 in the real world.this study will evaluate the optimized technical pathway and long-term tumor safety of slnb in patients with initial cn1 and nac downgrading to ycn0 in real-world studies. the main endpoint of the study was axillary recurrence free survival. the secondary study endpoints were regional lymph node recurrence free survival, disease-free survival, overall survival, incidence of postoperative upper limb lymphedema, and patient quality of life.

Eligibility criteria:
inclusion criteria: 1. patients with ecog score 0-1 points 2. patients with breast cancer stage ct1-3n1m0 (according to ajcc version 7) pathological diagnosis of ipsilateral axillary lymph node metastasis in patients with invasive breast cancer 3. patients with abnormal axillary lymph nodes ≤ 3 detected by imaging examination 4. patients with effective neoadjuvant therapy (cr+pr) 5. patients with clinical axillary negative ycn0 after neoadjuvant therapy 6. patients without prior history of ipsilateral axillary surgery and radiation therapy 7. patients without previous history of ipsilateral breast cancer (including carcinoma in situ) 8. patients without obvious contraindications for surgery or radiation therapy 9. no other history of malignant tumors within 5 years from enrollment in the study 10. patients who participate in other clinical trials at the same time and are judged by the researchers not to affect the study protocol can be enrolled normally 11. the patient voluntarily joined this study and signed an informed consent form. exclusion criteria: 1. stage iv (metastatic) breast cancer； 2. simultaneous double breast cancer； 3. baseline ct4; 4. baseline cn2-3 5. gestation 6. there are contraindications for slnb; 7. suffering from serious comorbidities or other comorbidities that may interfere with the planned treatment, or any other circumstances in which the researcher deems the patient unsuitable to participate in this study

Keywords: axillary sentinel lymph node biopsy
role of choline pet/ct in predicting survival in patients with hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: ¹¹c-choline positron emission tomography/computed tomography (pet/ct) has been used in patients with some types of solid cancers, but few data are available in patients undergoing hepatectomy for hepatocellular carcinoma (hcc). the aim of this study was to analyze the prognostic value of metabolic imaging data by using ¹¹c-choline pet/ct in patients with hcc before hepatectomy.

our prospectively maintained liver unit database was queried for patients with hcc preoperatively staged with ¹¹c-choline pet/ct. this metabolic imaging modality was performed in addition to standard abdominal ct or magnetic resonance imaging. several pet/ct parameters were recorded and analyzed. univariate and multivariate analyses were performed to identify whether those pet/ct parameters could be predictors of overall survival (os) and disease-free survival (dfs) of hcc patients.

Eligibility criteria:
inclusion criteria: * any patient with hcc candidate to surgical resection preoperatively staged with ¹¹c-choline pet/ct exclusion criteria: * r2 resection; * intraoperative use of rfa/mwi * postoperative death (90-days)
pantoprazole on insulin secretion in diabetes

Conditions: Type 2 Diabetes

Summary: the purpose of the study is to evaluate the effect of pantoprazole on insulin secretion in drug-naïve patients with type 2 diabetes.

type 2 diabetes mellitus (t2dm) has become a major health problem worldwide with a high prevalence and related mortality, and a high rate of disability in the economically active. in mexico the prevalence was 14.4% reported one of the highest in latin america and estimated a cost of $ 778 million allocated for this disease in 2010, i.e., the tenth place worldwide. within its pathophysiology are alterations in the secretion and insulin action, qualitatively and quantitatively, which implies a challenge for long-term metabolic control with the pharmacological arsenal available today. since the function of pancreatic β cell decreases as a function of time and lack of control is essential metabolic find drugs that can preserve pancreatic cell mass and even promote neogenesis, with the aim of restoring the physiological secretion of insulin have been lost in the early stages of type 2 diabetes to achieve optimal glycemic control sustained over time to avoid complications and reduce the costs associated with the disease. have been evaluated in animal models with promising results proton pumps inhibitors (ppi) for the restoration of glucose and the preservation of pancreatic cell function, including promoting its growth through increased levels of gastrin, which appears to act as a growth factor. however, at present no such mechanisms have been evaluated in humans, it would be interesting to assess the effect of administration of a ppi such as pantoprazole is, on the phases of insulin secretion in patients with t2dm recent diagnosis. material and methods: randomized, double-blind, placebo controlled clinical trial. population: 14 drug-naive adults patients with t2dm and obesity. hyperglycemic-hyperinsulinemic clamp to assess the phases of insulin secretion. intervention for 45 days: pantoprazole 40mg or placebo.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * drug-naive * no complications * hba1c 7 to \< 9% * fasting plasma glucose \< 210mg/dl * body mass index 30.0 to 39.9 and body weight stable for at least 3 months before the study * non smokers * blood pressure \< 130/80 exclusion criteria: * diabetes complications * women pregnant or stage of lactation * hepatic, renal, autoimmune disease * take drugs with effects on insulin secretion * zollinger-ellison disease * gastric or pancreatic tumor.

Keywords: diabetes insulin pantoprazole
leap motion based gamefication exercises in the individuals with systemic sclerosis

Conditions: Rheumatology; Scleroderma, Systemic; Video Games; Physiotherapy; Rehabilitation; Hand Rheumatism

Summary: leap motion based gamefication exercises in the individuals with systemic sclerosis

the aim of this project is to develop leap motion sensor-assisted rehabilitation games that can be easily applied in hand rehabilitation in individuals with ssc, motivating, directing to the right exercise, providing therapeutic evaluation and feedback during the game, and comparing the effectiveness of these rehabilitation games with traditional rehabilitation applications.

Eligibility criteria:
inclusion criteria: * having the ability to adapt to exercises * not having any diagnosed cardiac or orthopedic disease that may prevent the application of assessment methods exclusion criteria: * having a diagnosis of juvenile-onset ssc * having a history of neurological disease or trauma that will affect hand functions * receiving another treatment, such as intra-articular injection, surgery, that may affect hand rehabilitation in the last 6 months * having systemic involvement that may affect the treatment process or activities of daily living

Keywords: scleroderma, systemic hand therapy therapy, computer-assisted